Accendra Reports Q3 2026 Revenue Decline and Lowered Full-Year Guidance
Accendra (ACH) reported third-quarter revenue of $601.8 million, representing a 1% decline on a normalized basis following the termination of a major commercial contract and a non-core asset sale. The company faced significant headwinds, including a GAAP loss of $18.0 million compared to a $5.6 million loss in the prior year quarter. While the sleep category saw growth, other key segments like respiratory and diabetes experienced notable declines. Financial performance was further pressured by unfavorable category mix shifts and lower collection rates, leading to an adjusted EBITDA of $47.8 million. Consequently, management has revised its full-year revenue guidance to the bottom of its previous range and significantly lowered its full-year adjusted EBITDA forecast, suggesting it could be as much as 30% below the previously stated midpoint.
Topics: Adjusted EBITDA Category performance Diabetes category revenue GAAP Loss Net Revenue decline Respiratory category revenue